Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

PARP Inhibition in Cancer: An Update on Clinical Development.

Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM.

Target Oncol. 2019 Dec;14(6):657-679. doi: 10.1007/s11523-019-00680-2. Review.

PMID:
31625002
2.

Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.

Matsuo K, Cripe JC, Kurnit KC, Kaneda M, Garneau AS, Glaser GE, Nizam A, Schillinger RM, Kuznicki ML, Yabuno A, Yanai S, Garofalo DM, Suzuki J, St Laurent JD, Yen TT, Liu AY, Shida M, Kakuda M, Oishi T, Nishio S, Marcus JZ, Adachi S, Kurokawa T, Ross MS, Horowitz MP, Johnson MS, Kim MK, Melamed A, Machado KK, Yoshihara K, Yoshida Y, Enomoto T, Ushijima K, Satoh S, Ueda Y, Mikami M, Rimel BJ, Stone RL, Growdon WB, Okamoto A, Guntupalli SR, Hasegawa K, Shahzad MMK, Im DD, Frimer M, Gostout BS, Ueland FR, Nagao S, Soliman PT, Thaker PH, Wright JD, Roman LD.

Gynecol Oncol. 2019 Oct;155(1):39-50. doi: 10.1016/j.ygyno.2019.08.007. Epub 2019 Aug 16.

PMID:
31427143
3.

The duality of option-listing in cancer care.

Tate A, Rimel BJ.

Patient Educ Couns. 2020 Jan;103(1):71-76. doi: 10.1016/j.pec.2019.07.025. Epub 2019 Jul 24.

PMID:
31383562
4.

Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients.

Gresham G, Hendifar AE, Spiegel B, Neeman E, Tuli R, Rimel BJ, Figlin RA, Meinert CL, Piantadosi S, Shinde AM.

NPJ Digit Med. 2018 Jul 5;1:27. doi: 10.1038/s41746-018-0032-6. eCollection 2018.

5.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.

Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

PMID:
30948273
6.

Dicer1 Phosphomimetic Promotes Tumor Progression and Dissemination.

Aryal NK, Pant V, Wasylishen AR, Rimel BJ, Baseler L, El-Naggar AK, Mutch DG, Goodfellow PJ, Arur S, Lozano G.

Cancer Res. 2019 May 15;79(10):2662-2668. doi: 10.1158/0008-5472.CAN-18-2460. Epub 2019 Mar 26.

PMID:
30914430
7.

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.

Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel BJ, Buss MK, Nattam SR, Hurteau J, Luo W, Curtis J, Whalen C, Kohn EC, Ivy SP, Matulonis UA.

Ann Oncol. 2019 Apr 1;30(4):551-557. doi: 10.1093/annonc/mdz018.

PMID:
30753272
8.

Ultrasound guided transversus abdominis plane (TAP) block utilization in multimodal pain management after open gynecologic surgery.

Chang H, Rimel BJ, Li AJ, Cass I, Karlan BY, Walsh C.

Gynecol Oncol Rep. 2018 Oct 15;26:75-77. doi: 10.1016/j.gore.2018.10.007. eCollection 2018 Nov.

9.

The American Society of Clinical Oncology 2018 annual meeting: A review and summary of selected abstracts.

Rimel BJ, Gibson SJ, Beall SC, Monk BJ.

Gynecol Oncol. 2018 Nov;151(2):e1-e6. doi: 10.1016/j.ygyno.2018.08.018. Epub 2018 Aug 31. No abstract available.

PMID:
30174175
10.

Trends and outcomes of women with synchronous endometrial and ovarian cancer.

Matsuo K, Machida H, Blake EA, Holman LL, Rimel BJ, Roman LD, Wright JD.

Oncotarget. 2018 Jun 19;9(47):28757-28771. doi: 10.18632/oncotarget.25550. eCollection 2018 Jun 19.

11.

Aspirin use correlates with survival in women with clear cell ovarian cancer.

Wield AM, Walsh CS, Rimel BJ, Cass I, Karlan BY, Li AJ.

Gynecol Oncol Rep. 2018 Jun 9;25:78-81. doi: 10.1016/j.gore.2018.06.004. eCollection 2018 Aug.

12.

A contemporary framework of health equity applied to gynecologic cancer care: A Society of Gynecologic Oncology evidenced-based review.

Temkin SM, Rimel BJ, Bruegl AS, Gunderson CC, Beavis AL, Doll KM.

Gynecol Oncol. 2018 Apr;149(1):70-77. doi: 10.1016/j.ygyno.2017.11.013. Review.

PMID:
29605053
13.

An educational intervention to improve human papilloma virus (HPV) and cervical cancer knowledge among African American college students.

Staples JN, Wong MS, Rimel BJ.

Gynecol Oncol. 2018 Apr;149(1):101-105. doi: 10.1016/j.ygyno.2017.10.015.

PMID:
29605043
14.

Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.

Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W; Australian Ovarian Cancer Study Group, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Jung AY, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, du Bois A, Harter P, Schwaab I, Karlan BY, Lester J, Orsulic S, Rimel BJ, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MAT, Wu X, Lu KH, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LCV, Kopperud RK, Bjorge L, Kiemeney LA, Massuger LFAG, Pejovic T, Bruegl A, Cook LS, Le ND, Swenerton KD, Brooks-Wilson A, Kelemen LE, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Rzepecka IK, Webb PM; Ovarian Cancer Association Consortium.

Br J Cancer. 2018 Apr;118(8):1123-1129. doi: 10.1038/s41416-018-0011-3. Epub 2018 Mar 20.

15.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.

Lheureux S, McCourt C, Rimel BJ, Duska L, Fleming G, Mackay H, Mutch D, Temkin SM, Lynn J, Kohn EC.

Gynecol Oncol. 2018 Feb 22. pii: S0090-8258(18)30124-0. doi: 10.1016/j.ygyno.2018.02.005. [Epub ahead of print] Review.

PMID:
29477660
16.

Wearable activity monitors in oncology trials: Current use of an emerging technology.

Gresham G, Schrack J, Gresham LM, Shinde AM, Hendifar AE, Tuli R, Rimel BJ, Figlin R, Meinert CL, Piantadosi S.

Contemp Clin Trials. 2018 Jan;64:13-21. doi: 10.1016/j.cct.2017.11.002. Epub 2017 Nov 9. Review.

17.

The American Society of Clinical Oncology 2017 Annual Meeting: A review and summary of selected abstracts.

Rimel BJ, Gibson SJ, Sumner DA, Monk BJ.

Gynecol Oncol. 2017 Sep;146(3):443-448. doi: 10.1016/j.ygyno.2017.06.030. Epub 2017 Jul 8. No abstract available.

PMID:
28693948
18.

Rationale and study protocol for the Patient-Centered Outcome Aid (PCOA) randomized controlled trial: A personalized decision tool for newly diagnosed ovarian cancer patients.

Wenzel L, Mukamel D, Osann K, Havrilesky L, Sparks L, Lipscomb J, Wright AA, Walker J, Alvarez R, Van Le L, Robison K, Bristow R, Morgan R, Rimel BJ, Ladd H, Hsieh S, Wahi A, Cohn D.

Contemp Clin Trials. 2017 Jun;57:29-36. doi: 10.1016/j.cct.2017.03.006. Epub 2017 Mar 19. No abstract available.

19.

Chemotherapy completion in elderly women: can we identify those who behave younger than their stated age?

Rimel BJ.

Gynecol Oncol. 2017 Mar;144(3):449-450. doi: 10.1016/j.ygyno.2017.02.003. No abstract available.

PMID:
28212779
20.

The American Society of Clinical Oncology 2016 annual meeting: A review and summary of selected abstracts.

Rimel BJ, Gibson SJ, Sumner DA, Monk BJ.

Gynecol Oncol. 2017 Jan;144(1):e1-e7. doi: 10.1016/j.ygyno.2016.10.035. Epub 2016 Nov 5. No abstract available.

PMID:
27823770
21.

Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.

Zakhour M, Danovitch Y, Lester J, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I.

Gynecol Oncol. 2016 Nov;143(2):231-235. doi: 10.1016/j.ygyno.2016.08.336. Epub 2016 Sep 9.

PMID:
27623252
22.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators.

N Engl J Med. 2016 Dec 1;375(22):2154-2164. Epub 2016 Oct 7.

23.

Clinical Trial Accrual: Obstacles and Opportunities.

Rimel BJ.

Front Oncol. 2016 Apr 25;6:103. doi: 10.3389/fonc.2016.00103. eCollection 2016. Review. No abstract available.

24.

Recurrence and risk of progression to lower genital tract malignancy in women with high grade VAIN.

Hodeib M, Cohen JG, Mehta S, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I.

Gynecol Oncol. 2016 Jun;141(3):507-510. doi: 10.1016/j.ygyno.2016.03.033. Epub 2016 Apr 2.

PMID:
27032375
25.

A Delay from Diagnosis to Treatment Is Associated with a Decreased Overall Survival for Patients with Endometrial Cancer.

Dolly D, Mihai A, Rimel BJ, Fogg L, Rotmensch J, Guirguis A, Yordan E, Dewdney S.

Front Oncol. 2016 Feb 12;6:31. doi: 10.3389/fonc.2016.00031. eCollection 2016.

26.

The American Society of Clinical Oncology 51st Annual Meeting 2015: An overview and summary of selected abstracts.

Rimel BJ, Gibson SJ, Monk BJ.

Gynecol Oncol. 2015 Aug;138(2):227-34. doi: 10.1016/j.ygyno.2015.06.028. Epub 2015 Jun 27. No abstract available.

PMID:
26122660
27.

Too much, too late: Aggressive measures and the timing of end of life care discussions in women with gynecologic malignancies.

Zakhour M, LaBrant L, Rimel BJ, Walsh CS, Li AJ, Karlan BY, Cass I.

Gynecol Oncol. 2015 Aug;138(2):383-7. doi: 10.1016/j.ygyno.2015.06.001. Epub 2015 Jun 3.

PMID:
26049124
28.

Adnectin-targeted inhibitors: rationale and results.

Sachdev E, Gong J, Rimel B, Mita M.

Curr Oncol Rep. 2015 Aug;17(8):35. doi: 10.1007/s11912-015-0459-8.

PMID:
26045129
29.

A novel clinical trial recruitment strategy for women's cancer.

Rimel BJ, Lester J, Sabacan L, Park D, Bresee C, Dang C, Karlan B.

Gynecol Oncol. 2015 Aug;138(2):445-8. doi: 10.1016/j.ygyno.2015.05.008. Epub 2015 May 20.

PMID:
26001329
30.

Improving quality and decreasing cost in gynecologic oncology care. Society of gynecologic oncology recommendations for clinical practice.

Rimel BJ, Burke WM, Higgins RV, Lee PS, Lutman CV, Parker L.

Gynecol Oncol. 2015 May;137(2):280-4. doi: 10.1016/j.ygyno.2015.02.021. Epub 2015 Feb 28.

PMID:
25735256
31.

Statin use and survival in elderly patients with endometrial cancer.

Yoon LS, Goodman MT, Rimel BJ, Jeon CY.

Gynecol Oncol. 2015 May;137(2):252-7. doi: 10.1016/j.ygyno.2015.01.549. Epub 2015 Feb 7.

PMID:
25666607
32.

Breast cancer following ovarian cancer in BRCA mutation carriers.

Gangi A, Cass I, Paik D, Barmparas G, Karlan B, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF.

JAMA Surg. 2014 Dec;149(12):1306-13. doi: 10.1001/jamasurg.2014.1081. Erratum in: JAMA Surg. 2015 Feb;150(2):183.

PMID:
25372568
33.

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.

Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA.

Lancet Oncol. 2014 Oct;15(11):1207-14. doi: 10.1016/S1470-2045(14)70391-2. Epub 2014 Sep 10.

34.

The prognostic significance of lymphovascular space invasion in laparoscopic versus abdominal hysterectomy for endometrioid endometrial cancer.

Dewdney SB, Jiao Z, Roma AA, Gao F, Rimel BJ, Thaker PH, Powell MA, Massad LS, Mutch DG, Zighelboim I.

Eur J Gynaecol Oncol. 2014;35(1):7-10.

PMID:
24654453
35.

Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival.

Cohen JG, Tran AQ, Rimel BJ, Cass I, Walsh CS, Karlan BY, Li AJ.

Gynecol Oncol. 2014 Mar;132(3):556-9. doi: 10.1016/j.ygyno.2014.01.003. Epub 2014 Jan 11.

PMID:
24423879
36.

Post treatment surveillance of type II endometrial cancer patients.

Zakhour M, Li AJ, Walsh CS, Cass I, Karlan BY, Rimel BJ.

Gynecol Oncol. 2013 Dec;131(3):609-12. doi: 10.1016/j.ygyno.2013.09.008. Epub 2013 Sep 17.

PMID:
24051222
37.

Cost analysis of colposcopy for abnormal cytology in post-treatment surveillance for cervical cancer.

Tergas AI, Havrilesky LJ, Fader AN, Guntupalli SR, Huh WK, Massad LS, Rimel BJ.

Gynecol Oncol. 2013 Sep;130(3):421-5. doi: 10.1016/j.ygyno.2013.05.037. Epub 2013 Jun 5.

PMID:
23747836
38.

Cervicovaginal cytology in the detection of recurrence after cervical cancer treatment.

Rimel BJ, Ferda A, Erwin J, Dewdney SB, Seamon L, Gao F, DeSimone C, Cotney KK, Huh W, Massad LS.

Obstet Gynecol. 2011 Sep;118(3):548-53. doi: 10.1097/AOG.0b013e3182271fdd.

PMID:
21860282
39.

Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers.

Dewdney SB, Rimel BJ, Thaker PH, Thompson DM Jr, Schmidt A, Huettner P, Mutch DG, Gao F, Goodfellow PJ.

Clin Cancer Res. 2011 Apr 15;17(8):2120-9. doi: 10.1158/1078-0432.CCR-10-2668. Epub 2011 Mar 3.

40.

Inferior vena cava filter placement in the gynecologic oncology patient: A 15-year institutional experience.

Dewdney SB, Benn T, Rimel BJ, Gao F, Saad N, Vedantham S, Mutch DG, Zighelboim I.

Gynecol Oncol. 2011 May 1;121(2):344-6. doi: 10.1016/j.ygyno.2011.01.004. Epub 2011 Jan 26.

PMID:
21276606
41.

The role of neoadjuvant chemotherapy in the management of patients with advanced stage ovarian cancer: survey results from members of the Society of Gynecologic Oncologists.

Dewdney SB, Rimel BJ, Reinhart AJ, Kizer NT, Brooks RA, Massad LS, Zighelboim I.

Gynecol Oncol. 2010 Oct;119(1):18-21. doi: 10.1016/j.ygyno.2010.06.021. Epub 2010 Jul 31.

PMID:
20673970
42.

Infrequent methylation of the DUSP6 phosphatase in endometrial cancer.

Chiappinelli KB, Rimel BJ, Massad LS, Goodfellow PJ.

Gynecol Oncol. 2010 Oct;119(1):146-50. doi: 10.1016/j.ygyno.2010.06.015. Epub 2010 Jul 16.

43.

Syndromic diagnosis of malaria in rural Sierra Leone and proposed additions to the national integrated management of childhood illness guidelines for fever.

Nnedu ON, Rimel B, Terry C, Jalloh-Vos H, Baryon B, Bausch DG.

Am J Trop Med Hyg. 2010 Apr;82(4):525-8. doi: 10.4269/ajtmh.2010.09-0188.

44.

Discussion: 'Biomarkers for detection of early ovarian cancer' by Nosov et al.

Massad LS, Parks L, Rimel BJ, Kizer N, Ogutha J.

Am J Obstet Gynecol. 2009 Jun;200(6):e1-3. doi: 10.1016/j.ajog.2009.04.026. No abstract available.

PMID:
19482110
45.

Absence of MGMT promoter methylation in endometrial cancer.

Rimel BJ, Huettner P, Powell MA, Mutch DG, Goodfellow PJ.

Gynecol Oncol. 2009 Jan;112(1):224-8. doi: 10.1016/j.ygyno.2008.08.038. Epub 2008 Oct 29.

46.

Progestin treatment induces apoptosis and modulates transforming growth factor-beta in the uterine endometrium.

Rodriguez GC, Rimel BJ, Watkin W, Turbov JM, Barry C, Du H, Maxwell GL, Cline JM.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):578-84. doi: 10.1158/1055-9965.EPI-07-0551.

47.

Cancer of the cervix: current management and new approaches.

Shivnani AT, Rimel BJ, Schink J, Small W Jr.

Oncology (Williston Park). 2006 Nov;20(12):1553-60; discussion 1560-4, 1583, 1586. Review.

48.

Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr.

Shostak LD, Ludlow J, Fisk J, Pursell S, Rimel BJ, Nguyen D, Rosenblatt JD, Planelles V.

Exp Cell Res. 1999 Aug 25;251(1):156-65.

PMID:
10438581
49.

Lentivirus vectors using human and simian immunodeficiency virus elements.

White SM, Renda M, Nam NY, Klimatcheva E, Zhu Y, Fisk J, Halterman M, Rimel BJ, Federoff H, Pandya S, Rosenblatt JD, Planelles V.

J Virol. 1999 Apr;73(4):2832-40.

50.

Inhibition of HIV type 1 infection with a RANTES-IgG3 fusion protein.

Challita-Eid PM, Klimatcheva E, Day BT, Evans T, Dreyer K, Rimel BJ, Rosenblatt JD, Planelles V.

AIDS Res Hum Retroviruses. 1998 Dec 20;14(18):1617-24.

PMID:
9870314

Supplemental Content

Support Center